ArticleAmerican journal of cancer research2021
ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer.
Article in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 31 citations in OpenAlex.
- A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.The Journal of clinical investigation · 2025Trial
- Construction of a human epidermal growth factor receptor 2-related gene risk model for predicting breast cancer prognosis.Oncology letters · 2026Article
- Acyl-CoA thioesterases and their derived lipid mediators: linking Acyl-CoA metabolic reprogramming to the tumor microenvironment.Frontiers in immunology · 2026Review
- Very long-chain fatty acids accumulate in breast cancer tissue and serum.Cancer cell international · 2025Article
- Construction of a prognostic signature for breast cancer based on genes involved in unsaturated fatty acid biosynthesis.Translational cancer research · 2025Article
- Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance.Molecular oncology · 2025Article
- ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer.Frontiers in cell and developmental biology · 2025Article
- Itaconate targets the ERK2 signal to suppress estrogen receptor-positive breast cancer cell growth.American journal of cancer research · 2025Article
- A fatty acid metabolism-related genes model for predicting the prognosis and immunotherapy effect of lung adenocarcinoma.Cancer biomarkers : section A of Disease markers · 2024Article
- SPDYC serves as a prognostic biomarker related to lipid metabolism and the immune microenvironment in breast cancer.Immunologic research · 2024Article
- ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.Endocrinology · 2024Article
- Reversal of the tamoxifen‑resistant breast cancer malignant phenotype by proliferation inhibition with bromosulfonamidine amino‑podophyllotoxin.Oncology letters · 2024Article
- Roles of THEM4 in the Akt pathway: a double-edged sword.Journal of Zhejiang University. Science. B · 2024Review
- Construction and Analysis of a Mitochondrial Metabolism-Related Prognostic Model for Breast Cancer to Evaluate Survival and Immunotherapy.The Journal of membrane biology · 2024Article
- ELOVL2-AS1 suppresses tamoxifen resistance by sponging miR-1233-3p in breast cancer.Epigenetics · 2023Article
- Identification of critical prognosis signature associated with lymph node metastasis of stomach adenocarcinomas.World journal of surgical oncology · 2023Article
- Insight of a lipid metabolism prognostic model to identify immune landscape and potential target for retroperitoneal liposarcoma.Frontiers in immunology · 2023Article
- Expression of decitabine-targeted oncogenes in meningiomas in vivo.Neurosurgical review · 2022Article
- Identification and validation of a novel 16-gene prognostic signature for patients with breast cancer.Scientific reports · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic events have successfully explained the cause of various cancer types, but little is known about tamoxifen resistance (TamR) that induces cancer recurrence. In this study,
Indexed as
Identifiers
34249416PMC8263635W3136680610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.